GlassScriptPhysician profile
Sheetal Sharma
NPI 1437967288
$1,168.02
in general payments reported to CMS, 2019-2025
19 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $124.32 | 2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $111.91 | 2025 | |
| Aimmune Therapeutics, INC. | $107.32 | 2025 | Zenpep |
| Glaxosmithkline, LLC. | $102.46 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $88.79 | 2025 | |
| Exact Sciences Corporation | $84.06 | 2025 | The Cologuard Plus Collection Kit |
| Abbvie INC. | $78.10 | 2025 | |
| Phathom Pharmaceuticals, INC. | $74.10 | 2025 | Voquezna |
| Lilly USA, LLC | $73.17 | 2025 | Jardiance |
| Amgen INC. | $64.74 | 2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.76 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.88 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $41.08 | 2025 | |
| Intra-Sana Laboratories | $30.91 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Xeris Pharmaceuticals, INC. | $21.30 | 2025 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $21.04 | 2025 | Apretude, Cabenuva |
| Amneal Pharmaceuticals LLC | $16.27 | 2025 | Unithroid |
| Almatica Pharma LLC | $15.36 | 2025 | Teriparatide |
| Madrigal Pharmaceuticals | $14.45 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.